Corrigendum: Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination
Villanueva, Paola (Department of General Medicine, Royal Children's Hospital Melbourne (Austràlia))
Crawford, Nigel W. (Immunisation Service, Royal Children's Hospital Melbourne)
Croda, Mariana Garcia (Universidade Federal do Mato Grosso do Sul)
Collopy, Simone (Universidade Estadual do Rio de Janeiro. Department of Pediatrics)
Jardim, Bruno (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (Brasil))
de Almeida Pinto Jardim, Tyane (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (Brasil))
Manning, Laurens (Fiona Stanley Hospital (Austràlia))
Lucas, Michaela (QE2 Medical Centre (Austràlia))
Marshall, Helen (The University of Adelaide and Department of Paediatrics (Austràlia))
Prat i Aymerich, Cristina (Institut Germans Trias i Pujol)
Sawka, Alice (Royal Adelaide Hospital (Austràlia))
Sharma, Ketaki (The Children's Hospital at Westmead (Austràlia))
Troeman, Darren (University Medical Center Utrecht)
Wadia, Ushma (Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute (Austràlia))
Warris, Adilia (Great Ormond Street Hospital, London, UK)
Wood, Nicholas (University of Sydney)
Messina, Nicole L. (Infection and Immunity, Murdoch Children's Research Institute, (Austràlia))
Curtis, Nigel (The Royal Children's Hospital Melbourne)
Pittet, Laure F. (University of Geneva)

Fecha:	2023
Resumen:	The prevalence of scar formation following Bacille Calmette-Guérin (BCG) vaccination varies globally. The beneficial off-target effects of BCG are proposed to be stronger amongst children who develop a BCG scar. Within an international randomised trial ('BCG vaccination to reduce the impact of coronavirus disease 2019 (COVID-19) in healthcare workers'; BRACE Trial), this nested prospective cohort study assessed the prevalence of and factors influencing scar formation, as well as participant perception of BCG scarring 12 months following vaccination. Amongst 3071 BCG-recipients, 2341 (76%) developed a BCG scar. Scar prevalence was lowest in Spain and highest in UK. Absence of post-injection wheal (OR 0. 4, 95%CI 0. 2-0. 9), BCG revaccination (OR 1. 7, 95%CI 1. 3-2. 0), female sex (OR 2. 0, 95%CI 1. 7-2. 4), older age (OR 0. 4, 95%CI 0. 4-0. 5) and study country (Brazil OR 1. 6, 95%CI 1. 3-2. 0) influenced BCG scar prevalence. Of the 2341 participants with a BCG scar, 1806 (77%) did not mind having the scar. Participants more likely to not mind were those in Brazil, males and those with a prior BCG vaccination history. The majority (96%) did not regret having the vaccine. Both vaccination-related (amenable to optimisation) and individual-related factors affected BCG scar prevalence 12 months following BCG vaccination of adults, with implications for maximising the effectiveness of BCG vaccination.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	BCG vaccine ; BCG scar ; Vaccination technique ; Vaccine safety
Publicado en:	Heliyon, Vol. 9 N. 7 (june 2023) , ISSN 2405-8440
Obra relacionada:	Villanueva, Paola; Crawford, Nigel W.; Croda, Mariana Garcia; [et al.]. «Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination». Heliyon, Vol. 9 (april 2023) 10.1016/j.heliyon.2023.e15241

Article original: https://ddd.uab.cat/record/281658
DOI: 10.1016/j.heliyon.2023.e15821
PMID: 37484338

10 p, 2.0 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados